Orchestrating Scientists, Data, and AI to Discover New Drugs

About this episode

Scotch McClure discusses the role of AI in modern drug development and the mapping of peptides for new drug candidates.

Scotch McClure had a bold plan for Maxwell Biosciences to map and mine the roughly 3 percent of peptides circulating in human plasma. The company has harnessed AI to move from a massive and messy universe of human peptides to a small-molecule candidate that could offer a potential alternative to antibiotics, antifungals, and some antivirals. McClure, CEO of Maxwell, sat down with Nagaraja Srivatsan to discuss why he thinks AI is becoming the central engine that makes modern drug development not just faster but possible at all, how he sees AI as essential to filtering out the noise in vast datasets, and why organizations will need to surrender more of the scientific process to AI while constraining it with a clear vision and guardrails.

People in this episode

Host: Nagaraja Srivatsan

Guest: Scotch McClure

Topics covered

• drug development
• AI in healthcare
• peptide mapping
• antibiotic alternatives
• data analysis

Keywords

• AI
• drug discovery
• peptides
• Maxwell Biosciences
• antibiotics
• data mining
• healthcare

Mentioned in this episode

Organizations: Maxwell Biosciences

More episodes of Life Sciences DNA Podcast

• Lessons from Insmed’s Journey to an AI First Biotech · June 11, 2026 · 46 min
• Human Accountability in an Agentic Pharma World · May 28, 2026 · 49 min
• Making AI Transformations that Stick · May 14, 2026 · 53 min
• Finding ROI from AI in the Mundane · April 9, 2026 · 46 min
• A Pragmatic Path to AI-Enabled Commercial Operations · March 26, 2026 · 37 min
• Reimagining Scientific Work in the Age of AI Agents · March 12, 2026 · 47 min